<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05614089</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY21110122</org_study_id>
    <nct_id>NCT05614089</nct_id>
  </id_info>
  <brief_title>Human Versus Analogue Insulin for Youth With Type 1 Diabetes in Low-Resource Settings</brief_title>
  <acronym>HumAn-1</acronym>
  <official_title>Human Versus Analogue Insulin for Youth With Type 1 Diabetes in Low-Resource Settings: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jing Luo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Leona M. and Harry B. Helmsley Charitable Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this trial is to determine whether insulin glargine reduces the risk&#xD;
      of serious hypoglycemia or improves Time in Range at 6 months when compared against standard&#xD;
      of care human insulin (e.g. NPH or premixed 70/30) among youth living with type 1 diabetes&#xD;
      (T1D) in low resource settings.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Long-acting insulin analogues have become a de-facto standard of care for patients with T1D&#xD;
      living in high-income countries. Unfortunately, insulin analogues remain unavailable or&#xD;
      unaffordable for much of the global population. In both 2017 and 2019, applications to add&#xD;
      long-acting insulin analogues to the WHO's Model List of Essential Medicines (EML) were&#xD;
      rejected due to insufficient evidence of superiority and an unfavorable cost-effectiveness&#xD;
      profile when compared against older, less expensive, human insulins (e.g., NPH insulin and&#xD;
      premixed 70/30 insulin). In 2021, long-acting insulin analogues were added to the EML but the&#xD;
      decision remains controversial since the WHO concluded that &quot;magnitude of clinical benefit of&#xD;
      long-acting insulin analogues over human insulin for most clinical outcomes was small.&quot;&#xD;
      Moreover, studies that compare long-acting insulin analogues versus human insulins conducted&#xD;
      in high-income settings may not generalize to children and young adults living with T1D in&#xD;
      very low-resource settings.&#xD;
&#xD;
      To address this unmet need, Pitt has partnered with Brigham and Women's Hospital, The London&#xD;
      School of Hygiene and Tropical Medicine, the Clinton Health Access Initiative and Life For a&#xD;
      Child to conduct a randomized controlled trial comparing insulin glargine, a long-acting&#xD;
      analogue insulin, against intermediate human insulin among 400 children and young adults&#xD;
      living with T1D in a lower resource setting.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 28, 2023</start_date>
  <completion_date type="Anticipated">November 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2024</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time-in-serious hypoglycemia</measure>
    <time_frame>6 months after randomization</time_frame>
    <description>% spent less than 54mg/dl, averaged across all daily measures averaged across two CGM sensors</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time-in-range (TIR)</measure>
    <time_frame>6 months after randomization</time_frame>
    <description>% between 70 and 180mg/dl inclusive, averaged across two CGM sensors</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time-in-hypoglycemia</measure>
    <time_frame>6 months after randomization</time_frame>
    <description>% spent less than 70mg/dl</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-above-range</measure>
    <time_frame>6 months after randomization</time_frame>
    <description>% spent greater than 180mg/dl</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nocturnal hypoglycemic events</measure>
    <time_frame>6 months after randomization</time_frame>
    <description>Number of events (defined as &gt;=15mins in duration &lt; 70mg/dl) between 1200 and 0600</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycemic control (HbA1c)</measure>
    <time_frame>baseline, 3, 6, 9 and 12 months after randomization</time_frame>
    <description>Mean HbA1c lab result</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of severe hypoglycemic events</measure>
    <time_frame>6 months after randomization</time_frame>
    <description>Events requiring the assistance of an external third party person</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Diabetic Ketoacidosis</measure>
    <time_frame>6 months after randomization</time_frame>
    <description>Hospitalization or Emergency Room Visit with primary diagnosis of Diabetic Ketoacidosis. This will be measured by self-report and confirmed through review of hospital records</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (e.g. PedsQL Pediatric Quality of Life Inventory)</measure>
    <time_frame>Baseline and at 6 and 12 months after randomization</time_frame>
    <description>The PedsQLTM 3.2 Diabetes Module is composed of 33 items comprising 5 dimensions for ages 8- 45 years. Items are scaled on a 5-point scale from 0 (never) to 4 (almost always). Scores are transformed on a scale range from 0 to 100. The total score is the sum of all the items over the number of items answered on all scales.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>Glargine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Insulin glargine (long-acting insulin analogue)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NPH or premixed 70/30 (human insulin)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>NPH or premixed 70/30 (human insulin)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Glargine</intervention_name>
    <description>Formulation: Available as a clear liquid in a glass cartridge (1 cartridge =3ml=300 units).&#xD;
Route: Subcutaneous injection using insulin syringe and needle. At the site in Iraq, glargine will be available only as a prefilled, disposable pen (1 pen = 3ml = 300 units).&#xD;
Amount of each dose: varies depending on baseline basal insulin needs&#xD;
Dose escalation scheme: Participants randomly assigned to glargine will start with a dose that is generally equal to 80% of their total basal human insulin dose prior to the switch (per ISPAD guidelines and the switching guide developed by Life for a Child with the guidance of Dr. Ragnar Hanas and two other ISPAD members familiar with less-resourced settings).&#xD;
Frequency of dose: once per day (usually administered before bedtime)</description>
    <arm_group_label>Glargine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NPH or premixed 70/30 (human insulin)</intervention_name>
    <description>Drug: NPH or Premixed 70/30 Formulation: Available as a liquid in a glass vial or glass cartridge (10ml=1000IU). At the site in Iraq, NPH will be available only as a prefilled, disposable pen (1 pen = 3ml = 300 units).&#xD;
Route: Subcutaneous injection using insulin syringe and needle Amount of each dose: varies depending on baseline basal insulin needs (per usual care or treating clinician) Frequency of dose: once or twice per day (per usual care or treating clinician)&#xD;
Duration of therapy: 12 months&#xD;
Participants in both groups will receive the same frequency of blood glucose testing and same intensity of education and counseling (e.g. titration advice according to fasting glucose targets and strategies to avoid hypoglycemia). Participants in both groups will have equal access to test strips (sufficient to test up to 5 times per day during the active titration phase and after 3 times/day).</description>
    <arm_group_label>NPH or premixed 70/30 (human insulin)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Children and young adults (age 7-25)&#xD;
&#xD;
          2. Have a clinical diagnosis of type 1 diabetes (T1D)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior use of any insulin analogue&#xD;
&#xD;
          2. Patients (or parents for children &lt;18 years old) who refuse to or cannot provide&#xD;
             informed consent&#xD;
&#xD;
          3. Who are currently pregnant or plan to become pregnant over the next year&#xD;
&#xD;
          4. Who have previously used a continuous glucose monitor (CGM) for glucose monitoring&#xD;
&#xD;
          5. Who were first diagnosed with T1D less than 12 months ago&#xD;
&#xD;
          6. Who is diagnosed with severe malnutrition&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jing Luo, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jing Luo, MD, MPH</last_name>
    <phone>+1(412) 383-0627</phone>
    <email>luoj@pitt.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>BIRDEM Hospital</name>
      <address>
        <city>Dhaka</city>
        <country>Bangladesh</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bedowra Zabeen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bugando Medical Center</name>
      <address>
        <city>Mwanza</city>
        <country>Tanzania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Renatus Fabiano</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sekou-Toure Hospital</name>
      <address>
        <city>Mwanza</city>
        <country>Tanzania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Renatus Fabiano</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Bangladesh</country>
    <country>Tanzania</country>
  </location_countries>
  <verification_date>February 2023</verification_date>
  <study_first_submitted>October 28, 2022</study_first_submitted>
  <study_first_submitted_qc>November 4, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 14, 2022</study_first_posted>
  <last_update_submitted>February 28, 2023</last_update_submitted>
  <last_update_submitted_qc>February 28, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Jing Luo</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Type 1 Diabetes</keyword>
  <keyword>Insulin Glargine</keyword>
  <keyword>Human Insulin</keyword>
  <keyword>Insulin Analogue</keyword>
  <keyword>Bangladesh</keyword>
  <keyword>Tanzania</keyword>
  <keyword>Iraq</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified, summary level data will be shared with other researchers, upon request.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>2 years after conclusion of study</ipd_time_frame>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 20, 2022</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/89/NCT05614089/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 27, 2022</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/89/NCT05614089/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

